D octors could be able to spot people who are at higher risk of multiple sclerosis (MS) sooner after a new study helped to ...

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus ® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the ...

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis ...

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis ...

For decades, multiple sclerosis (MS) research has focused largely on the inflammatory lesions visible on MRI scans. Yet new ...

The 2024 McDonald criteria, published just before the 2025 ECTRIMS Congress, substantially expand criteria for a probable diagnosis of multiple sclerosis, experts report.

The FDA extended its decision date for investigational tolebrutinib in non-relapsing, secondary progressive multiple sclerosis (MS) to December 28, Sanofi said. The agency also opted to not approve ...

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug ...

The U.S. Food and Drug Administration is delaying by three months its decision on whether or not to approve tolebrutinib for ...

The company was expecting a decision from the FDA by Sept. 28 for its oral drug tolebrutinib, but an update to the drug’s ...

The revelation that endometriosis is linked to autoimmune disorders is opening up a whole new way to treat this painful and ...